


Listing of Claims:

1. (Currently amended) A compound or compounds of comprising formula I



wherein

R^1, R^2, R^3, R^4, R^5 each, independently of one another, are selected from the group consisting of H, A, OH, OA, alkenyl, alkynyl, NO_2 , NH_2 , NHA, NA_2 , Hal, CN, COOH, COOA, -OHet, -O-alkylene-Het, -O-alkylene- NR^8R^9 , CONR^8R^9 , $\text{CH}(\text{OH})-\text{A}_1$ and $-\text{C}(=\text{O})-\text{A}_2$, and

two adjacent radicals selected from R^1, R^2, R^3, R^4, R^5 together also selected from the group consisting of $-\text{O}-\text{CH}_2-\text{CH}_2-$, $-\text{O}-\text{CH}_2-\text{O}-$, $-\text{O}-\text{CH}_2-\text{CH}_2-\text{O}-$, $-\text{O}-\text{CA}_2-\text{O}-$ and $-\text{O}-\text{CF}_2-\text{O}-$

R^6, R^7 each, independently of one another, are selected from the group consisting of H, A, Hal, OH, OA and CN,

R^8, R^9 each, independently of one another, are H or alkyl having 1-6 C atoms, wherein one or two CH_2 groups may be optionally are replaced by O or N atoms,

Het comprises a mono- or bicyclic saturated, unsaturated or aromatic heterocycle having 1 to 4 N, O or S atoms, which may be heterocycle optionally is unsubstituted or mono-, di- or trisubstituted by Hal, A, OA, COOA, CN or carbonyl oxygen ($=\text{O}$),

A comprises alkyl having 1 to 10 C atoms, wherein, in addition, 1-7 H atoms ~~may~~ be optionally replaced by F or chlorine,

X, X' each, independently of one another is NH or is absent,

Hal is selected from the group consisting of F, Cl, Br and I, or

~~and pharmaceutically usable~~ acceptable derivatives, solvates, salts, tautomers, and stereoisomers thereof, ~~including~~ or mixtures thereof in all ratios.

2. (Currently amended) The compound or compounds according to Claim 1, wherein

X is NH or is absent,

X' is NH,

~~and pharmaceutically usable derivatives, solvates, salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.~~

3. (Currently amended) The compound or compounds according to Claim 1 wherein

R¹, R², R³, R⁴, R⁵ each, independently of one another, are selected from the group consisting of H, A, OH, OA, NO₂, NH₂, NHA, NA₂, Hal, CN, -OHet, -O-alkylene-Het, -O-alkylene-NR⁸R⁹, CH(OH)-A, and -C(=O)-A, and

two adjacent radicals selected from R¹, R², R³, R⁴, R⁵ together also are selected from the group consisting of -O-CH₂-CH₂-, -O-CH₂-O-, -O-CH₂-CH₂-O-, -O-CA₂-O- and -O-CF₂-O-

~~_____and pharmaceutically usable derivatives, solvates, salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.~~

4. (Currently amended) The compound or compounds according to Claim 1 wherein

Het comprises a monocyclic saturated heterocycle having 1 to 3 N, O or S atoms, which heterocycle is unsubstituted or ~~may be~~ optionally is monosubstituted by COOA or A;

~~_____and pharmaceutically usable derivatives, solvates, salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.~~

5. (Currently amended) The compound or compounds according to Claim 1 wherein

R^6, R^7 are H;

~~_____and pharmaceutically usable derivatives, solvates, salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.~~

6. (Currently amended) The compound or compounds according to Claim 1 wherein

R^8, R^9 are H;

~~_____and pharmaceutically usable derivatives, solvates, salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.~~

7. (Currently amended) The compound or compounds according to Claim 1

wherein

X is NH or is absent,

X' is NH,

R^1, R^2, R^3, R^4, R^5 each, independently of one another, are selected from the group consisting of H, A, OH, OA, NO_2 , NH_2 , NHA, NA_2 , Hal, CN, -OHet, -O-alkylene-Het, -O-alkylene- NR^8R^9 , $\text{CH}(\text{OH})\text{-A}$ and -C(=O)-A , and

two adjacent radicals selected from R^1, R^2, R^3, R^4, R^5 together also are selected from the group consisting of -O- $\text{CH}_2\text{-CH}_2\text{-}$, -O- $\text{CH}_2\text{-O-}$, -O- $\text{CH}_2\text{-CH}_2\text{-O-}$, -O- $\text{CA}_2\text{-O-}$ and -O- $\text{CF}_2\text{-O-}$,

Het comprises a monocyclic saturated heterocycle having 1 to 3 N, O or S atoms, which heterocycle is unsubstituted or ~~may be~~ optionally is monosubstituted by COOA or A,

R^6, R^7 is H,

R^8, R^9 each, independently of one another, are H or alkyl having 1-6 C atoms, wherein one or two CH_2 groups ~~may be~~ optionally are replaced by O or N atoms,

~~and pharmaceutically usable derivatives, solvates, salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.~~

8. (Currently amended) The compound or compounds according to Claim 1 wherein

X is NH or is absent,

X' is NH,

R^1, R^2, R^3, R^4, R^5 each, independently of one another, are selected from the group consisting of H, A, OH, OA, NO₂, NH₂, NHA, NA₂, Hal, CN, -OHet, -O-alkylene-Het, -O-alkylene-NR⁸R⁹, CH(OH)-A₂ and -C(=O)-A, and

two adjacent radicals selected from R^1, R^2, R^3, R^4, R^5 together also are selected from the group consisting of -O-CH₂-CH₂-, -O-CH₂-O-, -O-CH₂-CH₂-O-, -O-CA₂-O- and -O-CF₂-O-,

R^6, R^7 are H,

R^8, R^9 each, independently of one another, are H or alkyl having 1-6 C atoms, wherein one or two CH₂ groups ~~may be~~ optionally are replaced by O or N atoms,

Het comprises piperidinyl, pyrrolidinyl, morpholinyl or piperazinyl, each of which is unsubstituted or monosubstituted by COOA or A₂,

~~— and pharmaceutically usable derivatives, solvates, salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.~~

9. (Currently amended) The compound or compounds according to Claim 1, selected from the group consisting of

1-[4-(4-amino-5-oxo-5*H*-pyrido[2,3-*d*]pyrimidin-8-yl)phenyl]-3-(2-fluoro-5-trifluoromethyl phenyl)urea,

1-[4-(4-amino-5-oxo-5*H*-pyrido[2,3-*d*]pyrimidin-8-yl)phenyl]-3-(4-chloro-5-trifluoromethyl phenyl)urea,

1-[4-(4-amino-5-oxo-5*H*-pyrido[2,3-*d*]pyrimidin-8-yl)phenyl]-3-(2,4-difluorophenyl)urea,

1-[4-(4-amino-5-oxo-5*H*-pyrido[2,3-*d*]pyrimidin-8-yl)phenyl]-3-(2,6-difluorophenyl)urea,

1-[4-(4-amino-5-oxo-5*H*-pyrido[2,3-*d*]pyrimidin-8-yl)phenyl]-3-(3-fluoro-5-trifluoromethyl
phenyl)urea,

1-[4-(4-amino-5-oxo-5*H*-pyrido[2,3-*d*]pyrimidin-8-yl)phenyl]-3-(4-fluoro-5-trifluoromethyl
phenyl)urea,

1-[4-(4-amino-5-oxo-5*H*-pyrido[2,3-*d*]pyrimidin-8-yl)phenyl]-3-(4-methyl-5-trifluoromethyl
phenyl)urea,

1-[4-(4-amino-5-oxo-5*H*-pyrido[2,3-*d*]pyrimidin-8-yl)phenyl]-3-
(2,3,4,5,6-pentafluorophenyl)urea,

1-[4-(4-amino-5-oxo-5*H*-pyrido[2,3-*d*]pyrimidin-8-yl)phenyl]-3-
(2,4-dibromo-6-fluorophenyl)urea,

1-[4-(4-amino-5-oxo-5*H*-pyrido[2,3-*d*]pyrimidin-8-yl)phenyl]-3-(2-fluoro-6-trifluoromethyl
phenyl)urea,

1-[4-(4-amino-5-oxo-5*H*-pyrido[2,3-*d*]pyrimidin-8-yl)phenyl]-3-(2-fluoro-5-methylphenyl)
urea,

1-[4-(4-amino-5-oxo-5*H*-pyrido[2,3-*d*]pyrimidin-8-yl)phenyl]-3-(2,3,4-trifluorophenyl)urea,

1-[4-(4-amino-5-oxo-5*H*-pyrido[2,3-*d*]pyrimidin-8-yl)phenyl]-3-
(4-bromo-2,6-difluorophenyl)urea,

1-[4-(4-amino-5-oxo-5*H*-pyrido[2,3-*d*]pyrimidin-8-yl)phenyl]-3-(2-fluoro-3-trifluoromethylphenyl)urea,

1-[4-(4-amino-5-oxo-5*H*-pyrido[2,3-*d*]pyrimidin-8-yl)phenyl]-3-[2-(1-tert-butyloxycarbonylpiperidin-4-yl)phenyl]urea,

N-[4-(4-amino-5-oxo-5*H*-pyrido[2,3-*d*]pyrimidin-8-yl)phenyl]-2,4-dichlorobenzamide,

N-[4-(4-amino-5-oxo-5*H*-pyrido[2,3-*d*]pyrimidin-8-yl)phenyl]
-4-chloro-5-trifluoromethylbenzamide,

N-[4-(4-amino-5-oxo-5*H*-pyrido[2,3-*d*]pyrimidin-8-yl)phenyl]
-2-fluoro-5-trifluoromethylbenzamide,

1-[4-(4-amino-5-oxo-5*H*-pyrido[2,3-*d*]pyrimidin-8-yl)phenyl]-3-[3-chloro-5-trifluoromethyl-2-(piperidin-4-yloxy)phenyl]urea,

1-[4-(4-amino-5-oxo-5*H*-pyrido[2,3-*d*]pyrimidin-8-yl)phenyl]-3-[(2-fluoro-5-(2-dimethylaminoethoxy)phenyl]urea,

1-[4-(4-amino-5-oxo-5*H*-pyrido[2,3-*d*]pyrimidin-8-yl)phenyl]-3-[5-fluoro-2-(piperidin-4-yloxy)phenyl]urea,

1-[4-(4-amino-5-oxo-5*H*-pyrido[2,3-*d*]pyrimidin-8-yl)phenyl]-3-[4-chloro-5-trifluoromethyl-2-(piperidin-4-yloxy)phenyl]urea,

1-[4-(4-amino-5-oxo-5*H*-pyrido[2,3-*d*]pyrimidin-8-yl)phenyl]-3-[2-(piperidin-4-yloxy)phenyl]urea,

1-[4-(4-amino-5-oxo-5*H*-pyrido[2,3-*d*]pyrimidin-8-yl)phenyl]-3-[2-fluoro-5-(2-diethylaminoethoxy)phenyl]urea,

1-[4-(4-amino-5-oxo-5*H*-pyrido[2,3-*d*]pyrimidin-8-yl)phenyl]-3-[2-fluoro-5-[2-(piperidin-1-yl)ethoxy]phenyl]urea,

1-[4-(4-amino-5-oxo-5*H*-pyrido[2,3-*d*]pyrimidin-8-yl)phenyl]-3-[4-fluoro-2-(2-dimethylaminoethoxy)phenyl]urea,

1-[4-(4-amino-5-oxo-5*H*-pyrido[2,3-*d*]pyrimidin-8-yl)phenyl]-3-[4-fluoro-2-(2-diethylaminoethoxy)phenyl]urea,

1-[4-(4-amino-5-oxo-5*H*-pyrido[2,3-*d*]pyrimidin-8-yl)phenyl]-3-[3-chloro-4-[2-(morpholin-4-yl)ethoxy]phenyl]urea,

1-[4-(4-amino-5-oxo-5*H*-pyrido[2,3-*d*]pyrimidin-8-yl)phenyl]-3-[4-fluoro-2-[2-(morpholin-4-yl)ethoxy]phenyl]urea,

1-[4-(4-amino-5-oxo-5*H*-pyrido[2,3-*d*]pyrimidin-8-yl)phenyl]-3-[3-chloro-4-(2-dimethylaminoethoxy)phenyl]urea,

1-[4-(4-amino-5-oxo-5*H*-pyrido[2,3-*d*]pyrimidin-8-yl)phenyl]-3-[3-chloro-4-(2-diethylaminoethoxy)phenyl]urea,

1-[4-(4-amino-5-oxo-5*H*-pyrido[2,3-*d*]pyrimidin-8-yl)phenyl]-3-[4-chloro-2-(2-dimethylaminoethoxy)phenyl]urea,

1-[4-(4-amino-5-oxo-5*H*-pyrido[2,3-*d*]pyrimidin-8-yl)phenyl]-3-[2-chloro-5-(2-diethylaminoethoxy)phenyl]urea,

1-[4-(4-amino-5-oxo-5*H*-pyrido[2,3-*d*]pyrimidin-8-yl)phenyl]-3-[3-trifluoromethyl-6-[3-(morpholin-4-yl)propoxy]phenyl]urea,

1-[4-(4-amino-5-oxo-5*H*-pyrido[2,3-*d*]pyrimidin-8-yl)phenyl]-3-(2-{2-[(2-methoxyethyl)methylamino]ethoxy}-5-trifluoromethylphenyl)urea,

1-[4-(4-amino-5-oxo-5*H*-pyrido[2,3-*d*]pyrimidin-8-yl)phenyl]-3-(4-{2-[(2-methoxyethyl)methylamino]ethoxy}-3-trifluoromethylphenyl)urea,

1-[4-(4-amino-5-oxo-5*H*-pyrido[2,3-*d*]pyrimidin-8-yl)phenyl]-3-[3-trifluoromethyl-4-(2-methylaminoethoxy)phenyl]urea,

1-[4-(4-amino-5-oxo-5*H*-pyrido[2,3-*d*]pyrimidin-8-yl)phenyl]-3-[5-trifluoromethyl-2-(2-methylaminoethoxy)phenyl]urea,

1-[4-(4-amino-5-oxo-5*H*-pyrido[2,3-*d*]pyrimidin-8-yl)phenyl]-3-[3-trifluoromethyl-4-[3-(morpholin-4-yl)propoxy]phenyl]urea,

1-[4-(4-amino-5-oxo-5*H*-pyrido[2,3-*d*]pyrimidin-8-yl)phenyl]-3-[4-(1-methylpiperidin-4-yl)oxy]-3-trifluoromethylphenyl]urea,

1-[4-(4-amino-5-oxo-5*H*-pyrido[2,3-*d*]pyrimidin-8-yl)phenyl]-3-[4-(1-methylpiperidin-4-yl methoxy)-3-trifluoromethylphenyl]urea,

1-[4-(4-amino-5-oxo-5*H*-pyrido[2,3-*d*]pyrimidin-8-yl)phenyl]-3-[4-(piperidin-4-ylmethoxy)-3-trifluoromethylphenyl]urea,

1-[4-(4-amino-5-oxo-5*H*-pyrido[2,3-*d*]pyrimidin-8-yl)phenyl]-3-[2-(piperidin-4-yl-methoxy)-5-trifluoromethylphenyl]urea,

1-[4-(4-amino-5-oxo-5*H*-pyrido[2,3-*d*]pyrimidin-8-yl)phenyl]-3-[2-(1-methylpiperidin-4-yl methoxy)-5-trifluoromethylphenyl]urea,

1-[4-(4-amino-5-oxo-5*H*-pyrido[2,3-*d*]pyrimidin-8-yl)phenyl]-3-(2-fluorophenyl)urea,

1-[4-(4-amino-5-oxo-5*H*-pyrido[2,3-*d*]pyrimidin-8-yl)phenyl]-3-(3-trifluoromethylphenyl) urea,

1-[4-(4-amino-5-oxo-5*H*-pyrido[2,3-*d*]pyrimidin-8-yl)phenyl]-3-(3-bromo-5-trifluoromethyl phenyl)urea,

1-[4-(4-amino-5-oxo-5*H*-pyrido[2,3-*d*]pyrimidin-8-yl)phenyl]-3-benzo-1,3-dioxol-5-ylurea,

1-[4-(4-amino-5-oxo-5*H*-pyrido[2,3-*d*]pyrimidin-8-yl)phenyl]-3-(2,2-dimethylbenzo-1,3-dioxol-5-yl)urea,

1-[4-(4-amino-5-oxo-5*H*-pyrido[2,3-*d*]pyrimidin-8-yl)phenyl]-3-(3-trifluoromethoxyphenyl) urea,

1-[4-(4-amino-5-oxo-5*H*-pyrido[2,3-*d*]pyrimidin-8-yl)phenyl]-3-(4-trifluoromethylphenyl) urea,

1-[4-(4-amino-5-oxo-5*H*-pyrido[2,3-*d*]pyrimidin-8-yl)phenyl]-3-(2-methoxy-5-trifluoromethylphenyl)urea,

1-[4-(4-amino-5-oxo-5*H*-pyrido[2,3-*d*]pyrimidin-8-yl)phenyl]-3-(2-fluoro-5-methylphenyl) urea,

1-[4-(4-amino-5-oxo-5*H*-pyrido[2,3-*d*]pyrimidin-8-yl)phenyl]-3-(3-tert-butylphenyl)urea,

1-[4-(4-amino-5-oxo-5*H*-pyrido[2,3-*d*]pyrimidin-8-yl)phenyl]-3-(3-isopropylphenyl)urea,

1-[4-(4-amino-5-oxo-5*H*-pyrido[2,3-*d*]pyrimidin-8-yl)phenyl]-3-(3-acetylphenyl)urea,

1-[4-(4-amino-5-oxo-5*H*-pyrido[2,3-*d*]pyrimidin-8-yl)phenyl]-3-(4-methoxy-5-trifluoromethylphenyl)urea,

1-[4-(4-amino-5-oxo-5*H*-pyrido[2,3-*d*]pyrimidin-8-yl)phenyl]-3-[3-(2,2,2-trifluoro-1-hydroxyethyl)phenyl]urea,

1-[4-(4-amino-5-oxo-5*H*-pyrido[2,3-*d*]pyrimidin-8-yl)phenyl]-3-(3-ethylphenyl)urea,


1-[4-(4-amino-5-oxo-5*H*-pyrido[2,3-*d*]pyrimidin-8-yl)phenyl]-3-(2,2-difluorobenzo-1,3-dioxol-5-yl)urea, and

1-[4-(4-amino-5-oxo-5*H*-pyrido[2,3-*d*]pyrimidin-8-yl)phenyl]-3-(3-methoxy-5-trifluoromethylphenyl)urea, 471;

—~~and pharmaceutically usable~~ acceptable derivatives, solvates, salts, tautomers, and stereoisomers thereof, ~~including~~ and mixtures thereof in all ratios.


10. (Currently amended) A process for the preparation of the compound or compounds of the formula I Claim 1 ~~and pharmaceutically usable derivatives, salts, solvates, tautomers and stereoisomers thereof~~, comprising reacting

a compound of the formula II



wherein R^6 , R^7 , R^8 and R^9 have the meanings indicated in Claim 1,


with a compound of the formula III



wherein R^1 , R^2 , R^3 , R^4 and R^5 have the meanings indicated in Claim 1,

or

reacting a compound of the formula II with a compound of the formula IV



wherein R^1 , R^2 , R^3 , R^4 and R^5 have the meanings indicated in Claim 1,

and L comprises Cl, Br, I or a free or reactively functionally modified OH group,

or

a base or acid of the compound or compounds ~~formula-I~~ is converted into one of its salts.

11. (Currently amended) A pharmaceutical composition comprising at least one of the compound or compounds of the formula-I according to Claim 1 ~~pharmaceutically usable derivatives, salts, solvates, tautomers and stereoisomers thereof, including mixtures thereof in all ratios, and optionally in a pharmaceutical formulation and further optionally comprising~~ excipients or adjuvants.

12. (Currently amended) A method of treatment of diseases comprising inhibiting, regulating or modulating kinase signal transduction ~~comprising by~~ administering the compound or compounds of Claim 1 to a patient in need thereof, ~~a pharmaceutical composition according to Claim 11.~~

13. (Previously Presented) The method according to Claim 12, wherein said kinases are selected from the group consisting of tyrosine kinases and Raf kinases.

14. (Currently amended) The method according to Claim 13, wherein said tyrosine kinases are selected from the group consisting of TIE-2, VEGFR, PDGFR, FGFR and FLT/KDR.

15. (Canceled)

16. (Canceled)

17. (Currently amended) The method according to Claim 12 wherein one or more of said diseases comprises a solid tumor.

18. (Currently amended) The method according to Claim 17 wherein said solid tumour originates from the group consisting of tumours of the squamous epithelium, the bladder, ~~the~~ stomach, ~~the~~ kidneys, of head, ~~and~~ neck, the oesophagus, ~~the~~ cervix, ~~the~~ thyroid, ~~the~~ intestine, ~~the~~ liver, ~~the~~ brain, the prostate, ~~the~~ urogenital tract, ~~the~~ lymphatic system, the stomach, the larynx and ~~the~~ lung.

19. (Cancelled)

20. (Currently amended) The method according to Claim 17 wherein said solid tumour originates from the group consisting of lung adenocarcinoma, small-cell lung carcinomas, pancreatic cancer, glioblastomas, colon carcinoma and breast carcinoma.

21. (Currently amended) The method according to Claim ~~15~~ 17, wherein one or more of said diseases is a disease ~~tumour~~ of the blood ~~and~~ or immune system.

22. (Currently amended) The method according to Claim 21, wherein the ~~tumour~~ disease of the blood or immune system originates from the group consisting of monocytic leukemia acute myelotic leukaemia, chronic myelotic leukaemia, acute lymphatic leukaemia or chronic lymphatic leukaemia.

23. (Currently amended) The method according to Claim ~~15~~ 17 wherein the one or more said diseases is a disease in which angiogenesis is implicated.

24. (Currently amended) The method according to Claim 23, wherein the one or more said diseases is an ocular disease.

25. (Currently amended) The method according to Claim 24 wherein said ocular disease is selected from the group consisting of retinal vascularisation, diabetic retinopathy, age-induced macular degeneration and an inflammatory diseases.

26. (Currently amended) The method according to Claim 25, wherein said inflammatory disease originates from the group consisting of rheumatoid arthritis, psoriasis, contact dermatitis and delayed hypersensitivity reactions.

27. (Currently amended) The method according to Claim 12 wherein one or more said diseases comprise a disease of bone pathologies, wherein said bone pathology originates from the group consisting of osteosarcoma, osteoarthritis and rickets.

28. (Currently amended) The method according to Claim 12 ~~wherein said pharmaceutical composition is administered~~ comprising, administering the compound or compounds of Claim 1 to the patient in combination with a compound from the group consisting of 1) an oestrogen receptor modulator, 2) an androgen receptor modulator, 3) a retinoid receptor modulator, 4) a cytotoxic agent, 5) an antiproliferative agent, 6) a prenyl-protein transferase inhibitor, 7) an HMG-CoA reductase inhibitor, 8) an HIV protease inhibitor, 9) a reverse transcriptase inhibitor and 10) an ~~another~~ angiogenesis inhibitor.

29. (Currently amended) The method according to Claim 12 ~~wherein said pharmaceutical composition is administered~~ comprising, administering the compound or compounds of Claim 1 to the patient in combination with radiotherapy and a compound from the group consisting of 1) an oestrogen receptor modulator, 2) an androgen receptor modulator, 3) a retinoid receptor modulator, 4) a cytotoxic agent, 5) an antiproliferative agent, 6) a prenyl-protein transferase inhibitor, 7) an HMG-CoA reductase inhibitor, 8) an HIV protease inhibitor, 9) a reverse transcriptase inhibitor and 10) an ~~another~~ angiogenesis inhibitor.

30. (Currently amended) The method according to Claim 12

~~wherein said pharmaceutical composition is administered comprising, administering~~
the compound or compounds of Claim 1 to the patient in combination with a growth-factor receptor inhibitor.

31. (Canceled)

32. (Previously Presented) The method according to Claim 13 wherein said Raf kinase is selected from the group consisting of A-Raf, B-Raf and Raf-1.

33. (Currently amended) The method according to Claim 12 wherein said diseases are selected from the group consisting of hyperproliferative and non-hyperproliferative diseases.


34. (Previously Presented) The method according to Claim 12 wherein said disease is cancerous.

35. (Previously Presented) The method according to Claim 12 wherein said disease is non-cancerous.

36. (Currently amended) The method according to Claim 35, wherein one or more said non-cancerous diseases are selected from the group consisting of psoriasis, arthritis, inflammation, endometriosis, scarring, benign prostatic hyperplasia, immunological diseases, autoimmune diseases and immuno-deficiency diseases.

37. (Currently amended) The method according to Claim 34, wherein one or more said diseases are selected from the group consisting of brain cancer, lung cancer, squamous cell cancer, bladder cancer, gastric cancer, pancreatic cancer, hepatic cancer, renal cancer, colorectal cancer, breast cancer, head cancer, neck cancer, oesophageal cancer, gynaecological cancer, thyroid cancer, lymphoma, chronic leukaemia and acute leukaemia.

38. (Currently amended) A compound or compounds of ~~the~~ formula I-1



wherein

R^6 , R^7 each, independently of one another, are selected from the group consisting of H, A, Hal, OH, OA and CN,

R^8 , R^9 each, independently of one another, are H or A,

R^{10} is NH_2 or NO_2 ,

A in each case, independently of one another, is alkyl having 1 to 10 C atoms, wherein, in addition, 1-7 H atoms ~~may be~~ optionally are replaced by F or chlorine,

Hal are selected from the group consisting of F, Cl, Br and I,

and pharmaceutically acceptable derivatives, solvates, salts, tautomers and stereoisomers thereof, ~~including~~ or mixtures thereof in all ratios.

39. (Currently amended) The compound or compounds according to Claim 38

wherein

R^6, R^7 are H

R^8, R^9 are H,

~~_____ and solvates, salts, tautomers and stereoisomers thereof, including mixtures thereof in~~
all ratios.